Finance
settings
Theme
mobile
Device default
✓
dark_mode
Dark theme
light_mode
Light theme
Search labs
feedback
Send feedback
Sign in
Lists
playlist_add
New
4016
Research
4016:TADAWUL
check_indeterminate_small
Middle East Pharmaceutical Inds Co SJSC
SARÂ 62.75
arrow_upward
+1.21%
(
+0.75
) 1D
Aug 24, 3:14:35 PM GMT+3 · SAR
area_chart
Area
stacked_line_chart
Compare
search
close
All symbols
monitoring
Indicators
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
Symbol
Price
Change
% Change
Overview
Earnings
Financials
insights_auto
Generating top insights for 4016...
Open
SARÂ 62.00
High
SARÂ 63.45
Low
SARÂ 61.90
Mkt. cap
2.20B
Avg. vol.
63.30K
Volume
157.70K
Dividend
2.48%
Quarterly dividend
SARÂ 0.39
Ex-dividend date
Mar 30, 2026
P/E ratio
20.24
52-wk high
SARÂ 79.10
52-wk low
SARÂ 53.90
EPS
SARÂ 3.10
Shares outstanding
21.55M
No. of employees
731
Open
SARÂ 62.00
High
SARÂ 63.45
Low
SARÂ 61.90
Mkt. cap
2.20B
Avg. vol.
63.30K
Volume
157.70K
Dividend
2.48%
Quarterly dividend
SARÂ 0.39
Ex-dividend date
Mar 30, 2026
P/E ratio
20.24
52-wk high
SARÂ 79.10
52-wk low
SARÂ 53.90
EPS
SARÂ 3.10
Shares outstanding
21.55M
No. of employees
731
Related stocks
4072
Mbc Group LJSC
SARÂ 20.38
-0.97%
arrow_downward
8313
Rasan Information Technology Cmpny SCJSC
SARÂ 135.10
-0.95%
arrow_downward
4162
Almunajem Foods Company SJSC
SARÂ 61.35
-2.00%
arrow_downward
1322
Al Masane Al Kobra Mining Company SJSC
SARÂ 88.45
-0.06%
arrow_downward
About Middle East Pharmaceutical Inds Co SJSC
CEO
Mohamed Maher Al Ghannam
Employees
731
Founded
1998
Headquarters
Riyadh, Riyadh Province, Saudi Arabia
Sector
Pharmaceutical industry
Website
avalonpharmaceutical.com
Previous reports
All values in SAR
Loading Previous Earnings...
Income statement
Balance sheet
Cash flow
Income statement
Revenue
Net income
calendar_month
Quarterly
Quarterly
Annual
All values in SAR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
107.95M
137.52M
130.13M
136.48M
Cost of goods sold
45.81M
47.32M
49.78M
51.36M
Cost of revenue
45.81M
47.32M
49.78M
51.36M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
50.78M
43.26M
48.09M
51.16M
Operating expense
51.48M
43.77M
50.05M
51.43M
Total operating expenses
97.29M
91.08M
99.83M
102.79M
Operating income
10.66M
46.43M
30.30M
33.70M
Other non operating income
-
-
-
-
EBT including unusual items
9.82M
45.93M
29.13M
30.82M
EBT excluding unusual items
9.82M
45.89M
29.13M
30.82M
Income tax expense
1.54M
1.41M
2.23M
2.01M
Effective tax rate
15.69%
3.07%
7.67%
6.54%
Other operating expenses
-147.78K
-109.44K
-54.06K
-268.26K
Net income
8.28M
44.52M
26.90M
28.80M
Net profit margin
7.67%
32.38%
20.67%
21.10%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-844.49K
-562.26K
-1.16M
-2.88M
Net interest expenses
-844.49K
-562.26K
-1.16M
-2.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
13.78M
49.70M
33.47M
37.11M
Gain or loss from assets sale
-40.87K
-55.44K
-
-
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer
Ask anything
edit_square
New thread
notes_spark
Thread history
What's going on with the markets today?
search_spark
Create a portfolio
add
Create a task
task_spark
Deep Search
travel_explore
mic
Voice Search
add
Add Tool
upload_file
Upload File
bar_chart
Create portfolio
travel_explore
Deep Search
arrow_upward
Ask AI
search_spark
mic
Voice Search
add
Add Tool
upload_file
Upload File
bar_chart
Create portfolio
travel_explore
Deep Search
arrow_upward
Ask AI
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer